BR112012006252A2 - "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". - Google Patents

"formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".

Info

Publication number
BR112012006252A2
BR112012006252A2 BR112012006252A BR112012006252A BR112012006252A2 BR 112012006252 A2 BR112012006252 A2 BR 112012006252A2 BR 112012006252 A BR112012006252 A BR 112012006252A BR 112012006252 A BR112012006252 A BR 112012006252A BR 112012006252 A2 BR112012006252 A2 BR 112012006252A2
Authority
BR
Brazil
Prior art keywords
abt
crystalline forms
bcl
solvates
treatment
Prior art date
Application number
BR112012006252A
Other languages
English (en)
Inventor
G Z Zhang Geoff
D Catron Nathaniel
J Brackemeyer Paul
B Borchardt Thomas
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112012006252A2 publication Critical patent/BR112012006252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

a base livre de abt-263 e as formas cristalinas da mesma são ingredientes farmacêuticos ativos adequados para as composições farmacêuticas úteis no tratamento de uma doença caracterizada pela superexpressão de uma ou mais proteínas da família bcl-2 antiapoptóticas,por exemplo, câncer.
BR112012006252A 2009-09-20 2010-09-15 "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". BR112012006252A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24405109P 2009-09-20 2009-09-20
PCT/US2010/048949 WO2011034934A1 (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Publications (1)

Publication Number Publication Date
BR112012006252A2 true BR112012006252A2 (pt) 2017-05-23

Family

ID=43064468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006252A BR112012006252A2 (pt) 2009-09-20 2010-09-15 "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".

Country Status (15)

Country Link
US (2) US8362014B2 (pt)
EP (1) EP2477972A1 (pt)
JP (2) JP2013505249A (pt)
KR (1) KR20120085781A (pt)
CN (2) CN105820138A (pt)
AU (1) AU2010295717B2 (pt)
BR (1) BR112012006252A2 (pt)
CA (1) CA2771984A1 (pt)
IL (1) IL218403A0 (pt)
MX (1) MX2012003408A (pt)
NZ (1) NZ598461A (pt)
RU (1) RU2551376C2 (pt)
TW (1) TWI488853B (pt)
WO (1) WO2011034934A1 (pt)
ZA (1) ZA201202891B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101695327B1 (ko) 2008-11-07 2017-01-11 암젠 리서치 (뮌헨) 게엠베하 급성 림프구성 백혈병의 치료방법
PT3330293T (pt) * 2008-11-07 2019-10-18 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
EP2477972A1 (en) 2009-09-20 2012-07-25 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
WO2011079127A1 (en) 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PL3431475T3 (pl) * 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
CA2909380A1 (en) * 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
WO2015157120A1 (en) * 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
CN115279375A (zh) 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713507A (en) 1948-10-04 1955-07-19 Garlinghouse Brothers Concrete bucket
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7075365B1 (en) 2004-04-22 2006-07-11 Altera Corporation Configurable clock network for programmable logic device
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
CA2662320C (en) * 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
JP4202380B2 (ja) * 2006-10-17 2008-12-24 シャープ株式会社 画像形成装置
US20090149461A1 (en) 2007-12-06 2009-06-11 Abbott Laboratories Method of treating cancer
CN101220008B (zh) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8140876B2 (en) * 2009-01-16 2012-03-20 International Business Machines Corporation Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2010259520A (ja) 2009-04-30 2010-11-18 Motoji Ono 搬送機構、トレッドミル及びコンベア
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8291422B2 (en) * 2009-05-11 2012-10-16 Bbn Technologies Corp. Energy-aware computing environment scheduler
US20110047552A1 (en) * 2009-05-11 2011-02-24 Raytheon Bbn Technologies Corp. Energy-aware process environment scheduler
EP2477972A1 (en) 2009-09-20 2012-07-25 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
CN101798292A (zh) * 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
IL218403A0 (en) 2012-04-30
US8362014B2 (en) 2013-01-29
US20110294811A1 (en) 2011-12-01
TWI488853B (zh) 2015-06-21
NZ598461A (en) 2013-12-20
AU2010295717A1 (en) 2012-03-22
AU2010295717B2 (en) 2014-09-11
JP2013505249A (ja) 2013-02-14
KR20120085781A (ko) 2012-08-01
CN105820138A (zh) 2016-08-03
WO2011034934A1 (en) 2011-03-24
US20110071151A1 (en) 2011-03-24
US8513243B2 (en) 2013-08-20
EP2477972A1 (en) 2012-07-25
TW201116526A (en) 2011-05-16
CA2771984A1 (en) 2011-03-24
MX2012003408A (es) 2012-08-03
JP2015232006A (ja) 2015-12-24
RU2551376C2 (ru) 2015-05-20
ZA201202891B (en) 2013-09-25
CN102695702A (zh) 2012-09-26
RU2012115851A (ru) 2013-10-27

Similar Documents

Publication Publication Date Title
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
UY32598A (es) Sal de abt-263 y formas en estado sólido de la misma
PH12015502581B1 (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
SE0301700D0 (sv) Novel compounds
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
ATE474568T1 (de) Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
BR112013012740A2 (pt) sais e formas cristalinas de um agente que induz apoptose
MY143795A (en) Tetrahydropyridoindole derivatives
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
UY30759A1 (es) Compuestos quimicos
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
NO20090628L (no) Pyridizinon derivativater
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
NZ596047A (en) Stabilized lipid formulation of apoptosis promoter
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0818267A2 (pt) Novos derivados de 1,3-dihidro-5-isobenzofuranocarbonitrila e composição farmacêutica dos mesmos para o tratamento de ejaculação precoce
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]